BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23064281)

  • 1. Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines.
    Miyamoto Y; Nakagawa S; Wada-Hiraike O; Seiki T; Tanikawa M; Hiraike H; Sone K; Nagasaka K; Oda K; Kawana K; Nakagawa K; Fujii T; Yano T; Kozuma S; Taketani Y
    Oncol Rep; 2013 Jan; 29(1):51-7. PubMed ID: 23064281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
    Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
    Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells.
    Munagala R; Kausar H; Munjal C; Gupta RC
    Carcinogenesis; 2011 Nov; 32(11):1697-705. PubMed ID: 21859835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression.
    Brem GJ; Mylonas I; Brüning A
    Gynecol Oncol; 2013 Feb; 128(2):383-90. PubMed ID: 23107612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential treatment of HPV E6 and E7-expressing TC-1 cells with bortezomib and celecoxib promotes apoptosis through p-p38 MAPK-mediated downregulation of cyclin D1 and CDK2.
    Kim JE; Lee JI; Jin DH; Lee WJ; Park GB; Kim S; Kim YS; Wu TC; Hur DY; Kim D
    Oncol Rep; 2014 May; 31(5):2429-37. PubMed ID: 24627094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir.
    Bruning A; Vogel M; Mylonas I; Friese K; Burges A
    Curr Cancer Drug Targets; 2011 Sep; 11(7):799-809. PubMed ID: 21762082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
    Tsapakidis K; Vlachostergios PJ; Voutsadakis IA; Befani CD; Patrikidou A; Hatzidaki E; Daliani DD; Moutzouris G; Liakos P; Papandreou CN
    Int J Urol; 2012 Jun; 19(6):565-74. PubMed ID: 22324515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro.
    Chung WH; Sung BH; Kim SS; Rhim H; Kuh HJ
    Int J Oncol; 2009 Jun; 34(6):1669-79. PubMed ID: 19424586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic anticancer activity of 5-aminolevulinic acid photodynamic therapy in combination with low-dose cisplatin on Hela cells.
    Wei XQ; Ma HQ; Liu AH; Zhang YZ
    Asian Pac J Cancer Prev; 2013; 14(5):3023-8. PubMed ID: 23803073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity to Fas-mediated apoptosis in high-risk HPV-positive human cervical cancer cells: relationship with Fas, caspase-8, and Bid.
    Hougardy BM; van der Zee AG; van den Heuvel FA; Timmer T; de Vries EG; de Jong S
    Gynecol Oncol; 2005 May; 97(2):353-64. PubMed ID: 15863130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
    Festuccia C; Gravina GL; D'Alessandro AM; Muzi P; Millimaggi D; Dolo V; Ricevuto E; Vicentini C; Bologna M
    Endocr Relat Cancer; 2009 Jun; 16(2):401-13. PubMed ID: 19153211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bufalin enhances antitumor effect of paclitaxel on cervical tumorigenesis via inhibiting the integrin α2/β5/FAK signaling pathway.
    Liu F; Tong D; Li H; Liu M; Li J; Wang Z; Cheng X
    Oncotarget; 2016 Feb; 7(8):8896-907. PubMed ID: 26758421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.
    Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Dunner K; Huang P; Abbruzzese JL; McConkey DJ
    Cancer Res; 2005 Dec; 65(24):11658-66. PubMed ID: 16357177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB.
    Bastian L; Hof J; Pfau M; Fichtner I; Eckert C; Henze G; Prada J; von Stackelberg A; Seeger K; Shalapour S
    Clin Cancer Res; 2013 Mar; 19(6):1445-57. PubMed ID: 23357978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papilloma virus 16 E6 RNA interference enhances cisplatin and death receptor-mediated apoptosis in human cervical carcinoma cells.
    Tan S; Hougardy BM; Meersma GJ; Schaap B; de Vries EG; van der Zee AG; de Jong S
    Mol Pharmacol; 2012 May; 81(5):701-9. PubMed ID: 22328720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
    Wang Y; Rishi AK; Puliyappadamba VT; Sharma S; Yang H; Tarca A; Dou QP; Lonardo F; Ruckdeschel JC; Pass HI; Wali A
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):455-66. PubMed ID: 19960346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
    Sanchez E; Li M; Steinberg JA; Wang C; Shen J; Bonavida B; Li ZW; Chen H; Berenson JR
    Br J Haematol; 2010 Feb; 148(4):569-81. PubMed ID: 19958357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.